Impact of HCV genetic differences on pathobiology of disease

Expert Review of Anti-Infective Therapy

Volumn 9, Issue 9, 2011, Pages 747-759

  Ripoli, Maria ^a   Pazienza, Valerio ^a  

^a CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

Author keywords

fibrosis; HCV genotypes; hepatocellular carcinoma; insulin resistance; steatosis; treatment outcome

Indexed keywords

BOCEPREVIR; CYCLOPHILIN; NITAZOXANIDE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PEGINTERFERON; PEGINTERFERON ALPHA; PEGINTERFERON ALPHA2B; RIBAVIRIN; TELAPREVIR;

ANEMIA; ANTIVIRAL ACTIVITY; ANTIVIRAL SUSCEPTIBILITY; CANCER RISK; DISEASE ASSOCIATION; DISEASE COURSE; DRUG ERUPTION; DRUG PROTEIN BINDING; DRUG RESPONSE; FATTY LIVER; GASTROINTESTINAL DISEASE; GENETIC DIFFERENCE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INSULIN RESISTANCE; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FIBROSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PATHOGENICITY; REVIEW; RISK FACTOR;

ANTIVIRAL AGENTS; CARCINOMA, HEPATOCELLULAR; DISEASE PROGRESSION; ENZYME INHIBITORS; FATTY LIVER; GENETIC ASSOCIATION STUDIES; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HOST-PATHOGEN INTERACTIONS; HUMANS; INSULIN RESISTANCE; LIPID METABOLISM; LIVER CIRRHOSIS; LIVER NEOPLASMS; MOLECULAR TYPING; SEVERITY OF ILLNESS INDEX;

EID: 80052723449     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/eri.11.94     Document Type: Review

References (235)

1. Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. Lancet Infect. Dis. 5, 558-567 (2005). (Pubitemid 41196755)
2. Grakoui A, Wychowski C, Lin C, Feinstone SM, Rice CM. Expression and identification of hepatitis C virus polyprotein cleavage products. J. Virol. 67(3), 1385-1395 (1993). (Pubitemid 23067645)
3. Simmonds P, Holmes EC, Cha TA et al. Classification of hepatitis C virus into six major genotypes and a series of subtypes by phylogenetic analysis of the NS-5 region. J. Gen. Virol. 74, 2391-2399 (1993). (Pubitemid 23332300)
4. Okamoto H, Kurai K, Okada S et al. Full-length sequence of a hepatitis C virus genome having poor homology to reported isolates: comparative study of four distinct genotypes. Virology 188, 331-341 (1992).
5. Simmonds P. Genetic diversity and evolution of hepatitis C virus-15 years on. J. Gen. Virol. 85(Pt 11), 3173-3188 (2004). (Pubitemid 39445434)
6. Fukumoto T, Berg T, Ku Y et al. Viral dynamics of hepatitis C early after orthotopic liver transplantation: evidence for rapid turnover of serum virions. Hepatology 24, 1351-1354 (1996). (Pubitemid 26399029)
7. Neumann AU, Lam NP, Dahari H et al. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-α therapy. Science 282, 103-107 (1998). (Pubitemid 28471138)
8. Gomez J, Martell M, Quer J, Cabot B, Esteban JI. Hepatitis C viral quasispecies. J. Viral. Hepat. 6(1), 3-16 (1999). (Pubitemid 29077621)
9. Wohnsland A, Hofman WP, Sarrazin C. Viral determinants of resistance to treatment in patients with hepatitis C. Clin. Microbiol. Rev. 20(1), 23-38 (2007). (Pubitemid 46167766)
10. Li H, Sullivan DG, Feuerborn N, McArdle S, Bekele K, Pal S. Genetic diversity of hepatitis C virus predicts recurrent disease after liver transplantation. Virology 402(2), 248-255 (2010).
11. Webster G, Barnes E, Brown D, Dusheiko G. HCV genotypes - role in pathogenesis of disease and response to therapy. Baillieres Best Pract. Res. Clin. Gastroenterol. 14(2), 229-240 (2000). (Pubitemid 30398317)
12. Stoll-Keller F, Barth H, Fafi-Kremer S, Zeisel MB, Baumert TF. Development of hepatitis C virus vaccines: challenges and progress. Expert Rev. Vaccines 8(3), 335-345 (2009).
13. Goodman ZD, Ishak KG. Histopathology of hepatitis C virus infection. Sem. Liver Dis. 15, 70-81 (1995).
14. Shintani Y, Fujie H, Miyoshi H et al. Hepatitis C virus infection and diabetes: direct involvement of the virus in the development of insulin resistance. Gastroenterology 126, 840-848 (2004). (Pubitemid 38298332)
15. Hui JM, Sud A, Farrell GC et al. Insulin resistance is associated with chronic hepatitis C virus infection and fibrosis progression [corrected]. Gastroenterology 125, 1695-1704 (2003). (Pubitemid 37500434)
16. Petit JM, Bour JB, Galland-Jos C et al. Risk factors for diabetes mellitus and early insulin resistance in chronic hepatitis C. J. Hepatol. 35, 279-283 (2001). (Pubitemid 32803485)
17. Fartoux L, Poujol-Robert A, Guéchot J, Wendum D, Poupon R, Serfaty L. Insulin resistance is a cause of steatosis and fibrosis progression in chronic hepatitis C. Gut 54, 1003-1008 (2005). (Pubitemid 40873917)
18. Adinolfi LE, Gambardella M, Andreana A, Tripodi MF, Utili R, Ruggiero G. Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. Hepatology 33, 1358-1364 (2001). (Pubitemid 32496971)
19. Poynard T, Ratziu V, McHutchison J et al. Effect of treatment with peginterferon or interferon -2b and ribavirin on steatosis in patients infected with hepatitis C. Hepatology 38, 75-85 (2003). (Pubitemid 36775798)
20. Hui JM, Kench J, Farrell GC et al. Genotype specific mechanisms for hepatic steatosis in chronic hepatitis C infection. J. Gastroenterol. Hepatol. 17, 873-881 (2002).
21. Hezode C, Roudot-Thoraval F, Zafrani ES, Dhumeaux D, Pawlotsky JM. Different mechanisms of steatosis in hepatitis C virus genotypes 1 and 3 infections. J. Viral. Hepat. 11, 455-458 (2004). (Pubitemid 39336228)
22. Hourigan LF, Macdonald GA, Purdie D et al. Fibrosis in chronic hepatitis C correlates significantly with body mass index and steatosis. Hepatology 29, 1215-1219 (1999). (Pubitemid 29168757)
23. Camma C, Bruno S, Di Marco V et al. Insulin resistance is associated with steatosis in nondiabetic patients with genotype 1 chronic hepatitis C. Hepatology 43, 64-71 (2006). (Pubitemid 43738959)
24. Muzzi A, Leandro G, Rubbi-Brandt L et al. Insulin resistance is associated with liver fibrosis in non-diabetic chronic hepatitis C patients. J. Hepatol. 42, 41-46 (2005). (Pubitemid 40038898)
25. Moucari R, Asselah T, Cazals-Hatem D et al. Insulin resistance in chronic hepatitis C: association with genotypes 1 and 4, serum HCV RNA level, and liver fibrosis. Gastroenterology 134, 416-423 (2008). (Pubitemid 351181308)
26. White MF, Maron R, Kahn CR. Insulin rapidly stimulates tyrosine phosphorylation of a Mr-185,000 protein in intact cells. Nature 318, 183-186 (1985). (Pubitemid 16192587)
27. Tsakiridis T, McDowell HE, Walker T et al. Multiple roles of phosphatidylinositol 3-kinase in regulation of glucose transport, amino acid transport, and glucose transporters in L-6 skeletal muscle cells. Endocrinology 136, 4315-4322 (1995).
28. Hara K, Yonezawa K, Sakaue H et al. 1-Phosphatidylinositol 3-kinase activity is required for insulin-stimulated glucose transport but not for RAS activation in CHO cells. Proc. Natl Acad. Sci. USA 91, 7415-7419 (1994).
29. Shepherd PR, Nave BT, Siddle K. Insulin stimulation of glycogen synthesis and glycogen synthase activity is blocked by wortmannin and rapamycin in 3T3-L1 adipocytes: evidence for the involvement of phosphoinositide 3-kinase and p70 ribosomal protein-S6 kinase. Biochem. J. 305, 25-28 (1995).
30. Carlsen J, Christiansen K, Vinten J. Insulin stimulated glycogen synthesis in isolated rat hepatocytes: effect of protein kinase inhibitors. Cell Signal. 9(6), 447-450 (1997). (Pubitemid 27417170)
31. Okada T, Kawano Y, Sakakibara T, Hazeki O, Ui M. Essential role of phosphatidylinositol 3-kinase in insulin-induced glucose transport and antilipolysis in rat adipocytes. J. Biol. Chem. 269, 3568-3573 (1994).
32. Li J, Elberg G, Sekar N, He ZB, Shechter Y. Antilipolytic actions of vanadate and insulin in rat adipocytes mediated by distinctly different mechanism. Endocrinology 138, 2274-2279 (1997). (Pubitemid 27215225)
33. Morimoto C, Tsujita T, Okuda H. Antilipolytic actions of insulin on basal and hormone-induced lipolysis in rat adipocytes. J. Lipid. Res. 39, 957-962 (1998). (Pubitemid 28221999)
34. Mendez R, Myers M Jr, White MF, Rhoads RE. Stimulation of protein synthesis, eukaryotic translation initiation factor 4E phosphorylation, and PHAS-I phosphorylation by insulin requires insulin receptor substrate 1 and phosphatidylinositol 3-kinase. Mol. Cell. Biol. 16, 2857-2864 (1996).
35. Sutherland C, Waltner-Law M, Gnudi L, Kahn BB, Granner DK. Activation of the ras mitogen-αctivated protein kinase-ribosomal protein kinase pathway is not required for the repression of phosphoenolpyruvate carboxykinase gene transcription by insulin. J. Biol. Chem. 273, 3198-3204 (1998). (Pubitemid 28109728)
36. Valverde AM, Navarro P, Tervel T, Conejo R, Benito M, Lorenzo M. Insulin and insulin-like growth factor 1 up-regulate GLUT 4 gene expression in fetal brown adipocytes, in a phosphoinositide 3-kinase-dependent manner. Biochem. J. 337, 397-405 (1999).
37. Pazienza V, Clement S, Pugnale P et al. The hepatitis C virus core protein of genotypes 3a and 1b downregulates insulin receptor substrate 1 through genotype-specific mechanisms. Hepatology 45(5), 1164-1171 (2007). (Pubitemid 46775778)
38. Miyamoto H, Moriishi K, Moriya K et al. Involvement of the PA28g-dependent pathway in insulin resistance induced by hepatitis C virus core protein. J. Virol. 81, 1727-1735 (2007). (Pubitemid 46214447)
39. Kawaguchi T, Yoshida T, Harada M et al. Hepatitis C virus down-regulates insulin receptor substrates 1 and 2 through up-regulation of suppressor of cytokine. Am. J. Pathol. 165(5), 1499-1508 (2004). (Pubitemid 39435150)
40. Aytug S, Reich D, Sapiro LE, Bernstein D, Begum N. Impaired IRS-1/PI3-kinase signaling in patients with HCV: a mechanism for increased prevalence of Type 2 diabetes. Hepatology 38, 1384-1392 (2003). (Pubitemid 37466964)
41. Yao ZQ, Waggoner SN, Cruise MW et al. SOCS1 and SOCS3 are targeted by hepatitis C virus core/gC1qR ligation to inhibit T-cell function. J. Virol. 79, 15417-15429 (2005). (Pubitemid 43032324)
42. Walsh MJ, Jonsson JR, Richardson MM et al. Non-response to antiviral therapy is associated with obesity and increased hepatic expression of SOCS-3 in patients with chronic hepatitis C, viral genotype 1 Gut 55, 529-535 (2006).
43. Bode JG, Ludwig S, Ehrhardt C et al. IFN-α antagonistic activity of HCV core protein involves induction of suppressor of cytokine signaling-3 FASEB J. 17, 488-490 (2003).
44. Calegari VC, Alves M, Picardi PK et al. Suppressor of cytokine signaling-3 provides a novel interface in the cross-talk between angiotensin II and insulin signaling systems. Endocrinology 146, 579-588 (2005). (Pubitemid 40129813)
45. Banerjee S, Saito K, Ait-Goughoulte M, Meyer K, Ray RB, Ray R. Hepatitis C virus core protein upregulates serine phosphorylation of insulin receptor substrate-1 and impairs the downstream akt/protein kinase B signaling pathway for insulin resistance. J. Virol. 82(6), 2606-2612 (2008). (Pubitemid 351329151)
46. Crespo J, Riviero M, Fabrega E et al. Plasma leptin and TNF-α levels in chronic hepatitis C patients and their relationship to hepatic fibrosis. Dig. Dis. Sci. 47(7), 1604-1610 (2002). (Pubitemid 34753942)
47. Kallinowski B, Haseroth K, Marinos G et al. Induction of tumour necrosis factor (TNF) receptor type p55 and p75 in patients with chronic hepatitis C virus (HCV) infection. Clin. Exp. Immunol. 111, 269-277 (1998). (Pubitemid 28088306)
48. Nelson DR, Lim HL, Marousis CG et al. Activation of tumor necrosis factor-α system in chronic hepatitis C virus infection. Dig. Dis. Sci. 42, 2487-2494 (1997). (Pubitemid 28103785)
49. Zylberberg H, Rimaniol AC, Pol S et al. Soluble tumor necrosis factor receptors in chronic hepatitis C: a correlation with histological fibrosis and activity. J. Hepatol. 30(2), 185-191 (1999). (Pubitemid 29071178)
50. Moriishi K, Okabayashi T, Nakai K et al. Proteasome activator PA28g-dependent nuclear retention and degradation of hepatitis C virus core protein. J. Virol. 77, 10237-10249 (2003). (Pubitemid 37129667)
51. Akuta N, Suzuki F, Hirakawa M et al. Amino acid substitutions in the hepatitis C virus core region of genotype 1b are the important predictor of severe insulin resistance in patients without cirrhosis and diabetes mellitus. J. Med. Virol. 81, 1032-1039 (2009).
52. Tachi Y, Katano Y, Honda T et al. Impact of amino acid substitutions in the hepatitis C virus genotype 1b core region on liver steatosis and hepatic oxidative stress in patients with chronic hepatitis C. Liver Int. 30, 554-559 (2010).
53. Akuta N, Suzuki F, Kawamura Y et al. Amino acid substitutions in the hepatitis C virus core region are the important predictor of hepatocarcinogenesis. Hepatology 46, 1357-1364 (2007). (Pubitemid 350155517)
54. Kobayashi M, Akuta N, Suzuki F et al. Influence of aminoacid polymorphism in the core protein on progression of liver disease in patients infected with hepatitis C virus genotype 1b. J. Med. Virol. 82, 41-48 (2010).
55. Fishman SL, Factor SH, Balestrieri C et al. Mutations in the hepatitis C virus core gene are associated with advanced liver disease and hepatocellular carcinoma. Clin. Cancer Res. 15, 3205-3213 (2009).
56. Hu Z, Muroyama R, Kowatari N, Chang J, Omata M, Kato N. Characteristic mutations in hepatitis C virus core gene related to the occurrence of hepatocellular carcinoma. Cancer Sci. 100, 2465-2468 (2009).
57. An J, Muoio DM, Shiota M et al. Hepatic expression of malonyl-CoA decarboxylase reverses muscle, liver and whole-αnimal insulin resistance. Nat. Med. 10, 268-274 (2004). (Pubitemid 38667617)
58. Cohen B, Novick D, Rubinstein M. Modulation of insulin activities by leptin. Science 274, 1185-1188 (1996). (Pubitemid 26389283)
59. Colditz GA, Willett WC, Rotnitzky A, Manson JE. Weight gain as a risk factor for clinical diabetes mellitus in women. Ann. Intern. Med. 122, 481-486 (1995).
60. Elghouhari HM, Cesario KB, Lopez R, Zein NN. Pioglitazone improves early virologic kinetic response to PEG INF/RBV combination therapy in hepatitis C genotype 1 naive pts. Hepatology 48, 383A (2008).
61. Overbeck K, Genné D, Golay A, Negro F. Pioglitazone in chronic hepatitis C not responding to pegylated interferon-α and ribavirin. Swiss Association for the Study of the Liver (SASL).J. Hepatol. 49(2), 295-298 (2008).
62. Negro F. Correction of insulin resistance in chronic hepatitis C patients not responding to the standard of care: more questions than answers. INSPIRED-HCV Study Group. J. Hepatol. 50(6), 1271-1272 (2009).
63. Romero-Gomez M, Del Mar Viloria M, Andrade RJ et al. Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. Gastroenterology 128, 636-664 (2005).
64. Pazienza V, Vinciguerra M, Andriulli A, Mangia A. Hepatitis C virus core protein genotype 3a increases SOCS-7 expression through PPAR-{g} in Huh-7 cells. J. Gen. Virol. 91(Pt 7), 1678-1686 (2010).
65. Lonardo A, Adinolfi LE, Loria P, Carulli N, Ruggiero G, Day CP. Steatosis and hepatitis C virus: mechanisms and significance for hepatic and extrahepatic disease. Gastroenterology 126, 586-597 (2004). (Pubitemid 38182315)
66. Hwang SJ, Luo JC, Chu CW et al. Hepatic steatosis in chronic hepatitis C virus infection: prevalence and clinical correlation. J. Gastroenterol. Hepatol. 16, 190-195 (2001).
67. Tsutsumi T, Suzuki T, Shimoike T et al. Interaction of hepatitis C virus core protein with retinoid X receptor a modulates its transcriptional activity. Hepatology 35, 937-946 (2002). (Pubitemid 34258390)
68. Abid K, Pazienza V, De Gottardi A et al. An in vitro model of hepatitis C virus genotype 3-αssociated triglycerides accumulation. J. Hepatol. 42, 744-751 (2005).
69. Hourioux C, Patient R, Morin A et al. The genotype 3-specific hepatitis C virus core protein residue phenylalanine 164 increases steatosis in an in vitro cellular model. Gut 56, 1302-1308 (2007). (Pubitemid 47300434)
70. Piodi A, Chouteau P, Lerat H, Hezode C , Pawlotsky JM. Morphological changes in intracellular lipid droplets induced by different hepatitis C virus genotype core sequences and relationship with steatosis. Hepatology 48, 16-27 (2008). (Pubitemid 351975527)
71. Barba G, Harper F, Harada T et al. Hepatitis C virus core protein shows a cytoplasmic localization and associates to cellular lipid storage droplets. Proc. Natl Acad. Sci. USA 94, 1200-1205 (1997). (Pubitemid 27087828)
72. Chang ML, Yeh CT, Chen JC et al. Altered expression patterns of lipid metabolism genes in an animal model of HCV core-related, nonobese, modest hepatic steatosis. BMC Genomics 9, 109 (2008).
73. Moriya K, Yotsuyanagi H, Shintani Y et al. Hepatitis C virus core protein induces hepatic steatosis in transgenic mice. J. Gen. Virol. 78, 1527-1531 (1997). (Pubitemid 27343089)
74. Perlemuter G, Sabile A, Letteron P et al. Hepatitis C virus core protein inhibits microsomal triglyceride transfer protein activity and very low density lipoprotein secretion: a model of viral-related steatosis. FASEB J. 16, 185-194 (2002). (Pubitemid 34113012)
75. Lerat H, Honda M, Beard MR et al. Steatosis and liver cancer in transgenic mice expressing the structural and non-structural proteins of hepatitis C virus. Gastroenterology 122, 352-365 (2002). (Pubitemid 34116987)
76. Shi ST, Polyak SJ, Tu H, Taylor DR, Gretch DR, Lai MM. Hepatitis C virus NS5A colocalizes with the core protein on lipid droplets and interacts with apolipoproteins. Virology 292, 198-210 (2002). (Pubitemid 34920540)
77. Jackel-Cram C, Babiuk LA, Liu QJ. Up-regulation of fatty acid synthase promoter by hepatitis C virus core protein: genotype-3a core has a stronger effect than genotype-1b core. Hepatology 46(6), 999-1008 (2007). (Pubitemid 46669729)
78. Kim KH, Hong SP, Kim K, Park MJ, Kim KJ, Cheong J. HCV core protein induces hepatic lipid accumulation by activating SREBP1 and PPARc. Biochem. Biophys. Res. Commun. 355(4), 883-888 (2007). (Pubitemid 46366910)
79. Okuda M, Li K, Beard MR et al. Mitochondrial injury, oxidative stress, and antioxidant gene expression are induced by hepatitis C virus core protein. Gastroenterology 122, 366-375 (2002). (Pubitemid 34116988)
80. Waris G, Felmlee DJ, Negro F, Siddiqui A. Hepatitis C virus induces proteolytic cleavage of sterol regulatory element binding proteins and stimulates their phosphorylation via oxidative stress. J. Virol. 81(15), 8122-8130 (2007). (Pubitemid 47101498)
81. Moriya K, Fujie H, Shintani Y et al. The core protein of hepatitis C virus induces hepatocellular carcinoma in transgenic mice. Nat. Med. 4, 1065-1067 (1998). (Pubitemid 28417341)
82. Grassi A, Ballardini G, Susca M et al. HCV liver infection and liver steatosis: evidence for indirect mechanisms in genotype 3? Aliment. Pharmacol. Ther. 22, 79-82 (2005). (Pubitemid 41568545)
83. Asselah T, Boyer N, Marcellin P. Steatosis in hepatitis C: what does it mean? Gastroenterol. Clin. Biol. 27(12), 1073-1075 (2003). (Pubitemid 38120637)
84. Patton HM, Patel K, Behling C et al. The impact of steatosis on disease progression and early and sustained treatment response in chronic hepatitis C patients. J. Hepatol. 40, 484-490 (2004). (Pubitemid 38230851)
85. Kumar D, Farrell GC, Fung C, George G. Hepatitis C virus genotype 3 is cytopathic to hepatocytes: reversal of hepatic steatosis after sustained therapeutic response. Hepatology 36(5), 1266-1272 (2002). (Pubitemid 35253445)
86. Rubbi-Brandt L, Quadri R, Abid K et al. Hepatocyte steatosis is a cytopathic effect of hepatitis C virus genotype 3 J. Hepatol. 33, 106-115 (2000). (Pubitemid 30418941)
87. Castera L, Hézode C, Roudot-Thoraval F et al. Worsening of steatosis is an independent factor of fibrosis progression in untreated patients with chronic hepatitis C and paired liver biopsies. Gut 52, 288-292 (2003). (Pubitemid 36115074)
88. Fujimoto T, Ohsaki Y, Cheng J, Suzuki M, Shinohara Y. Lipid droplets: a classic organelle with new outfits. Histochem. Cell. Biol. 130(2), 263-279 (2008).
89. Miyanari Y, Atsuzawa K, Usuda N et al. The lipid droplet is an important organelle for hepatitis C virus production. Nat. Cell. Biol. 9, 1089-1097 (2007). (Pubitemid 47338147)
90. Gonzalez-Peralta RP, Fang JW, Davis GL et al. Optimization for the detection of hepatitis C virus antigens in the liver. J. Hepatol. 20, 143-147 (1994). (Pubitemid 24043100)
91. Yap SH, Willems M, Van den Oord J et al. Detection of hepatitis C virus antigen by immuno-histochemical staining: a histological marker of hepatitis C virus infection. J. Hepatol. 20, 275-281 (1994). (Pubitemid 24086844)
92. Hope RG, McLauchlan J. Sequence motifs required for lipid droplet association and protein stability are unique to the hepatitis C virus core protein. J. Gen. Virol. 81(Pt 8), 1913-1925 (2000). (Pubitemid 30599171)
93. Jhaveri R, McHutchison J, Patel K, Qiang G, Diehl AM. Specific polymorphisms in hepatitis C virus genotype 3 core protein associated with intracellular lipid accumulation. J. Infect. Dis. 197, 283-291 (2008). (Pubitemid 351263449)
94. Choi J, Ou JH. Mechanisms of liver injury. III. Oxidative stress in the pathogenesis of hepatitis C virus. Am. J. Physiol. Gastrointest. Liver Physiol. 290(5), G847-G851 (2006).
95. Vidali M, Tripodi MF, Ivaldi A et al. Interplay between oxidative stress and hepatic steatosis in the progression of chronic hepatitis C. J. Hepatol. 48(3), 399-406 (2008).
96. NIH consensus statement on management of hepatitis C: 2002 NIH Consens. State Sci. Statements 19(3), 1-46 (2002).
97. Missale G, Bertoni R, Lamonaca V et al. Different clinical behaviors of acute hepatitis C virus infection are associated with different vigor of the anti-viral cell-mediated immune response. J. Clin. Invest. 98(3), 706-714 (1996). (Pubitemid 26349175)
98. Zein NN, Li H, Persing DH. Humoral immunity in acute and chronic hepatitis C infection. Gastroenterology 117(2), 510 (1999). (Pubitemid 29352962)
99. Amoroso P, Rapicetta M, Tosti ME et al. Correlation between virus genotype and chronicity rate in acute hepatitis C. J. Hepatol. 28, 939-944 (1998). (Pubitemid 28275970)
100. Nousbaum JB, Pol S, Nalpas B, Landais P, Berthelot P, Brechot C. Hepatitis C virus type 1b (II) infection in France and Italy. Collaborative Study Group. Ann. Intern. Med. 122, 161-168 (1995).
101. Pozzato G, Moretti M, Franzin F et al. Severity of liver disease with different hepatitis C viral clones. Lancet 338, 509 (1991).
102. Ratziu V, Saboury M, Poynard T. Worsening of steatosis and fibrosis progression (comment).Gut 52, 1386-1387 (2003). (Pubitemid 37026480)
103. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. Lancet 349, 825-832 (1997). (Pubitemid 27129209)
104. Seeff LB. Natural history of hepatitis C. Am. J. Med. 107, S10-S15 (1999).
105. Deuffic-Burban S, Poynard T, Valleron AJ. Quantification of fibrosis progression in patients with chronic hepatitis C using a Markov model. J. Viral. Hepat. 9, 114-122 (2002). (Pubitemid 36002474)
106. Ortiz V, Berenguer M, Rayon JM, Carrasco D, Berenguer J. Contribution of obesity to hepatitis C-related fibrosis progression. Am. J. Gastroenterol. 97, 2408-2414 (2002).
107. Serfaty L, Poujol-Robert A, Carbonell N, Chazouilleres O, Poupon RE, Poupon R. Effect of the interaction between steatosis and alcohol intake on liver fibrosis progression in chronic hepatitis C. Am. J. Gastroenterol. 97, 1807-1812 (2002). (Pubitemid 34761411)
108. Wiley TE, McCarthy M, Breidi L, Layden TJ. Impact of alcohol on the histological and clinical progression of hepatitis C infection. Hepatology 28, 805-809 (1998). (Pubitemid 28405433)
109. Pistello M, Maggi F, Vatteroni L et al. Prevalence of hepatitis C virus genotypes in Italy. J. Clin. Microbiol. 32, 232-234 (1994). (Pubitemid 24016818)
110. Pozzato G, Moretti M, Croce LS et al. Interferon therapy in chronic hepatitis C virus: evidence of different outcome with respect to different viral strains. J. Med. Virol. 45, 445-450 (1995).
111. Silini E, Bono F, Cividini A et al. Differential distribution of hepatitis C virus genotypes in patients with and without liver function abnormalities. Hepatology 21, 285-290 (1995).
112. Zein NN, Rakela J, Poterucha JJ, Steers JL, Wiesner RH, Persing DH. Hepatitis C genotypes in liver transplant recipients: distribution and 1-year follow-up. Liver Transpl. Surg. 1(6), 354-357 (1995).
113. Zein NN, Rakela J, Krawitt EL et al. Hepatitis C virus genotypes in the United States: epidemiology, pathogenicity, and response to interferon therapy. Ann. Intern. Med. 125, 634-639 (1996). (Pubitemid 126450598)
114. Monto A, Alonzo J, Watson JJ, Grunfeld C, Wright TL. Steatosis in chronic hepatitis C: relative contributions of obesity, diabetes mellitus, and alcohol. Hepatology 36, 729-736 (2002). (Pubitemid 34977185)
115. Czaja AJ, Carpenter HA, Santrach PJ, Moore SB. Host- and disease-specific factors affecting steatosis in chronic hepatitis C. J. Hepatol. 29, 198-206 (1998). (Pubitemid 28352804)
116. Bochud PY, Cai T, Overbeck K et al. Genotype 3 is associated with accelerated fibrosis progression in chronic hepatitis. J. Hepatol. 51(4), 655-666 (2009).
117. Westin J, Nordlinder H, Lagging M, Norkrans G, Wejstal R. Steatosis accelerates fibrosis development over time in hepatitis C virus genotype 3 infected patients. J. Hepatol. 37, 837-842 (2002). (Pubitemid 35404224)
118. Rubbi-Brandt L, Fabris P, Paganin S et al. Steatosis affects chronic hepatitis C progression in a genotype specific way. Gut 53(3), 406-412 (2004). (Pubitemid 38241339)
119. Leandro G, Mangia A, Hui J et al. Relationship between steatosis, inflammation, and fibrosis in chronic hepatitis C: a met-αnalysis of individual patient data. Gastroenterology 130, 1636-1642 (2006).
120. Cua IH, Hui JM, Kench JG, George J. Genotype-specific interactions of insulin resistance, steatosis, and fibrosis in chronic hepatitis C. Hepatology 48(3), 723-731 (2008).
121. Kasprzak A, Zabel M, Biczysko W et al. Expression of cytokines (TNF-α, IL-1α, and IL-2) in chronic hepatitis C: Comparative Hybridocytochemical and Immunocytochemical Study in children and adult patients. J. Histochem. Cytochem. 52(1), 29-38 (2004). (Pubitemid 38032131)
122. Bruno S, Crosignani A, Maisonneuve P, Rossi S, Silini E, Mondelli MU. Hepatitis C virus genotype 1b as a major risk factor associated with hepatocellular carcinoma in patients with cirrhosis: a seventeen-year prospective cohort study. Hepatology 46, 1350-1356 (2007). (Pubitemid 350155516)
123. Brechot C. Hepatitis C virus: molecular biology and genetic variability. Dig. Dis. Sci. 41(Suppl. 12), S6-S21 (1996).
124. Shimotohno K. Hepatitis C virus as a causative agent of hepatocellular carcinoma. Intervirology 38, 162-169 (1995). (Pubitemid 26009387)
125. Raimondi S, Bruno S, Mondelli MU, Maisonneuve P. Hepatitis C virus genotype 1b as a risk factor for hepatocellular carcinoma development: a met-αnalysis. J. Hepatol. 50(6), 1142-1154 (2009).
126. De Mitri MS, Poussin K, Baccarini P et al. HCV-αssociated liver cancer without cirrhosis. Lancet 345, 413-415 (1995).
127. Madhoun MF, Fazili J, Bright BC, Bader T, Roberts DN, Bronze MS. Hepatitis C prevalence in patients with hepatocellular carcinoma without cirrhosis. Am. J. Med. Sci. 339, 169-173 (2010).
128. Hoofnagle JH. Course and outcome of hepatitis C. Hepatology 36, S21-S29 (2002). (Pubitemid 35253460)
129. McHutchison JG, Gordon SC, Schiff ER et al. Interferon -2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N. Engl. J. Med. 339, 1485-1492 (1998). (Pubitemid 28543496)
130. Liang TJ, Rehermann B, Seeff LB, Hoofnagle JH. Pathogenesis, natural history, treatment, and prevention of hepatitis C. Ann. Intern. Med. 132, 296-305 (2000). (Pubitemid 30106261)
131. Davis GL, Lau JY. Factors predictive of a beneficial response to therapy of hepatitis C. Hepatology 26, S122-S127 (1997).
132. Yoshioka K, Kakumu S, Wakita T et al. Detection of hepatitis C virus by polymerase chain reaction and response to interferon-α therapy: relationship to genotypes of hepatitis C virus. Hepatology 16, 293-299 (1992).
133. Roffi L, Redaelli A, Colloredo G et al. Outcome of liver disease in a large cohort of histologically proven chronic hepatitis C: influence of HCV genotype. Eur. J. Gastroenterol. Hepatol. 13, 501-506 (2001). (Pubitemid 32466251)
134. Tanaka H, Tsukuma H, Yamano H et al. Hepatitis C virus 1b (II) infection and development of chronic hepatitis, liver cirrhosis and hepatocellular carcinoma: a case-control study in Japan. J. Epidemiol. 8, 244-249 (1998). (Pubitemid 128788434)
135. Nishise Y, Saito T, Sugahara K et al. Risk of hepatocellular carcinoma and secondary structure of hepatitis C virus (HCV) NS3 protein amino-terminus, in patients infected with HCV subtype 1b. J. Infect. Dis. 196, 1006-1009 (2007). (Pubitemid 47580293)
136. Ishido S, Hotta H. Complex formation of the nonstructural protein 3 of hepatitis C virus with the p53 tumor suppressor. FEBS Lett. 438, 258-262 (1998). (Pubitemid 28529285)
137. Basu A, Meyer K, Lai KK et al. Microarray analyses and molecular profiling of Stat3 signaling pathway induced by hepatitis C virus core protein in human hepatocytes. Virology 349, 347-358 (2006). (Pubitemid 43782881)
138. Ray RB, Lagging LM, Meyer K, Steele R, Ray R. Transcriptional regulation of cellular promoters by hepatitis C virus core protein. Virus Res. 37, 209-220 (1995).
139. Hayashi J, Aoki H, Kajino K, Moriyama M, Arakawa Y, Hino O. Hepatitis C virus core protein activates the MAPK/ERK cascade synergistically with tumor promoter TPA, but not with epidermal growth factor or transforming growth factor a. Hepatology 32(5), 958-961 (2000).
140. Koike K. Steatosis, liver injury, and hepatocarcinogenesis in hepatitis C viral infection. J. Gastroenterol. 44(Suppl. 19), 82-88 (2009).
141. Arora P, Kim EO, Jung JK, Jang KL. Hepatitis C virus core protein downregulates E-cadherin expression via activation of DNA methyltransferase 1 and 3b. Cancer Lett. 261(2), 244-252 (2008).
142. Eng F, Klepper A, Walewski JL et al. Internal initiation stimulates production of p8 minicore, a member of a newly discovered family of hepatitis C virus core protein isoforms. J. Virol. 83(7), 3104-3114 (2009).
143. Strader DB, Wright T, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C. American Association for the study of liver diseases. Hepatology 39, 1147 (2004).
144. Causse X, Godinot H, Chevallier M et al. Comparison of 1 or 3 μ of interferon -2b and placebo in patients with chronic non-α, non-B hepatitis. Gastroenterology 101, 497-502 (1991).
145. Karino Y, Matsushima T, Saga A, Tsuyuguchi M, Miyazaki T, Toyota J. Treatment of chronic non-α, non-B hepatitis with interferon. Gastroenterology 26(Suppl. 3), 234-238 (1991).
146. Weiland O, Zhang YY, Widell A. Serum HCV RNA levels in patients with chronic hepatitis C given a second course of interferon -2b treatment after relapse following initial treatment. Scand. J. Infect. Dis. 25, 25-30 (1993). (Pubitemid 23099583)
147. Fried MW, Shiffman ML, Reddy KR et al. Peginterferon -2a plus ribavirin for chronic hepatitis C virus infection. N. Engl. J. Med. 347(13), 975-982 (2002).
148. Hadziyannis SJ, Sette H Jr, Morgan TR et al. Peginterferon-α2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann. Intern. Med. 140(5), 346-355 (2004).
149. Manns MP, McHutchison JG, Gordon SC et al. Peginterferon -2b plus ribavirin compared with interferon -2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358(9286), 958-965 (2001). (Pubitemid 32913521)
150. Poynard T, Marcellin P, Lee SS et al. Randomised trial of interferon -2b plus ribavirin for 48 weeks or for 24 weeks versus interferon -2b placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 352, 1426-1432 (1998). (Pubitemid 28510876)
151. Dalgard O, Mangia A. Short-term therapy for patients with hepatitis C virus genotype 2 or 3 infection. Drugs 66(14), 1807-1815 (2006). (Pubitemid 44584004)
152. von Wagner M, Huber M, Berg T et al. Peginterferon-2a (40 kDa) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C. Gastroenterology 129(2), 522-527 (2005). (Pubitemid 41096640)
153. Nguyen MH, Keeffe EB. Prevalence and treatment of hepatitis C virus genotypes 4, 5, and 6 Clin. Gastroenterol. Hepatol. 3(10 Suppl. 2), S97-S101 (2005). (Pubitemid 41427738)
154. Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 49, 1335-1374 (2009).
155. Welker MW, Zeuzem S. Occult hepatitis C: how convincing are the current data? Hepatology 49, 665-675 (2009).
156. Bruno S, Shiffman ML, Roberts SK et al. Efficacy and safety of peginterferon -2a (40kD) plus ribavirin in hepatitis C patients with advanced fibrosis and cirrhosis. Hepatology 51, 388-397 (2010).
157. Muir AJ, Bornstein JD, Killenberg PG. Peginterferon -2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites. N. Engl. J. Med. 350, 2265-2271 (2004). (Pubitemid 38669209)
158. Reddy KR, Messinger D, Popescu M, Hadziyannis SJ. Peginterferon -2a (40 kDa) and ribavirin: comparable rates of sustained virological response in sub-sets of older and younger HCV genotype 1 patients. J. Viral. Hepat. 16, 724-731 (2009).
159. Conjeevaram HS, Fried MW, Jeffers LJ et al. Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1 Gastroenterology 131, 470-477 (2006). (Pubitemid 44142464)
160. Ge D, Fellay J, Thompson AJ et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 461, 399-401 (2009).
161. Suppiah V, Moldovan M, Ahlenstiel G et al. IL28B is associated with response to chronic hepatitis C interferon-α and ribavirin therapy. Nat. Genet. 41, 1100-1104 (2009).
162. Tanaka Y, Nishida N, Sugiyama M et al. Genome-wide association of IL28B with response to pegylated interferon-α and ribavirin therapy for chronic hepatitis C. Nat. Genet. 41, 1105-1109 (2009).
163. Hayashi J, Kishihara Y, Yoshimura E et al. Relationship of genotype to level of hepatitis C viraemia determined by competitive polymerase chain reaction. J. Infect. 30, 235-239 (1995).
164. Enomoto N, Sakuma I, Asahina Y et al. Comparison of full length sequences of interferon sensitive and resistant hepatitis C virus 1b. J. Clin. Invest. 96, 224-230 (1995).
165. Paterson M, Laxton CD, Thomas HC, Ackrill AM, Foster GR. Hepatitis C virus NS5A protein inhibits interferon antiviral activity, but the effects do not correlate with clinical response. Gastroenterology 117, 1187-1197 (1999). (Pubitemid 29512679)
166. Aizaki H, Saito S, Ogino T et al. Suppression of interferon-induced antiviral activity in cells expressing hepatitis C virus proteins. J. Interferon Cytokine Res. 20, 1111-1120 (2000). (Pubitemid 32015251)
167. Nousbaum JB, Polyak SJ, Ray SC et al. Prospective characterization of full-length hepatitis C virus NS5A quasispecies during induction and combination antiviral therapy. J. Virol. 74, 9028-9038 (2000).
168. Williams BR. Signal integration via PKR. Sci. STKE 89, re2 (2001).
169. Gale M, Korth M, Tang N et al. Evidence that hepatitis C virus resistance to interferon is mediated through repression of the PKR protein kinase by the nonstructural 5A protein. Virology 230, 217-227 (1997). (Pubitemid 27211852)
170. Bossemeyer D. Protein kinases - structure and function. FEBS Lett. 369, 57-61 (1995).
171. Taylor SS, Knighton DR, Zheng J, Sowadski JM, Gibbs CS, Zoller MJ. A template for the protein kinase family. Trends Biochem. Sci. 18, 84-89 (1993). (Pubitemid 23080698)
172. Polyak SJ, Khabar KS, Paschal DM et al. Hepatitis C virus nonstructural 5A protein induces interleukin-8, leading to partial inhibition of the interferon-induced antiviral response. J. Virol. 75, 6095-6106 (2001). (Pubitemid 32553140)
173. Polyak SJ, Khabar KS, Rezeiq M, Gretch DR. Elevated levels of interleukin-8 in serum are associated with hepatitis C virus infection and resistance to interferon therapy. J. Virol. 75, 6209-6211 (2001). (Pubitemid 32553153)
174. Girard S, Shalhoub P, Lescure P et al. An altered cellular response to interferon and up-regulation of interleukin-8 induced by the hepatitis C viral protein NS5A uncovered by microarray analysis. Virology 295, 272-283 (2002). (Pubitemid 34921313)
175. Khabar KS, Al-Zoghaibi F, Al-αhdal MN et al. The a chemokine, interleukin 8, inhibits the antiviral action of interferon a. J. Exp. Med. 186, 1077-1085 (1997). (Pubitemid 27441151)
176. Akuta N, Suzuki F, Hirakawa M et al. Amino acid substitution in HCV core region and genetic variation near the IL28B gene affect viral dynamics during telaprevir, peginterferon and ribavirin treatment. Intervirology DOI: 101159/000323526 (2011) (Epub ahead of print).
177. Hsu CS, Hsu SJ, Chen HC et al. Association of IL28B gene variations with mathematical modeling of viral kinetics in chronic hepatitis C patients with IFN plus ribavirin therapy. Proc. Natl Acad. Sci. USA 108(9), 3719-3724 (2011).
178. Zeuzem S, Berg T, Moeller B et al. Expert opinion on the treatment of patients with chronic hepatitis C. J. Viral. Hepat. 16, 75-90 (2009).
179. McHutchison JG, Everson GT, Gordon SC et al. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N. Engl. J. Med. 360, 1827-1838 (2009).
180. McHutchison JG, Manns MP, Muir AJ et al. Telaprevir for previously treated chronic HCV infection. N. Engl. J. Med. 362, 1292-1303 (2010).
181. Hezode C, Forestier N, Dusheiko G et al. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N. Engl. J. Med. 360, 1839-1845 (2009).
182. Kwo PY, Lawitz EJ, McCone J et al. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon -2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre Phase 2 trial. Lancet 28, 376(9742), 705-716 (2010).
183. Foster GR, Hezode C, Bronowicki JP et al. Activity of telaprevir alone or in combination with peginterferon -2a and ribavirin in treatment-naive genotype 2 and 3 hepatitis-C patients: interim results of study C209 J. Hepatol. 50(Suppl. 1), S22 (2009).
184. Benhamou Y, Moussalli J, Ratziu V et al. Results of a prove of concept study (C210) of telaprevir monotherapy and in combination with peginterferon -2a and ribavirin in treatment-naive genotype 4 HCV patients. J. Hepatol. 50(Suppl. 1), S6 (2009).
185. Forestier N, Susser S, Welker MW et al. Long term follow-up of patients previously treated with telaprevir. Hepatology 48(Suppl. 1), 760 (2008).
186. McCown MF, Rajyaguru S, Kular S, Cammack N, Najera I. GT-1a or GT-1b subtype-specific resistance profiles for hepatitis C virus inhibitors telaprevir and HCV-796 Antimicrob. Agents Chemother. 53, 2129-2132 (2009).
187. Lin C, Gates CA, Rao BG et al. In vitro studies of crossresistance mutations against two hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061 J. Biol. Chem. 280, 36784-36791 (2005). (Pubitemid 41587758)
188. Lin K, Kwong AD, Lin C. Combination of a hepatitis C virus NS3-NS4A protease inhibitor and a interferon synergistically inhibits viral RNA replication and facilitates viral RNA clearance in replicon cells. Antimicrob. Agents Chemother. 48, 4784-4792 (2004). (Pubitemid 39577685)
189. Lin K, Perni RB, Kwong AD, Lin C. VX-950, a novel hepatitis C virus (HCV) NS3-4A protease inhibitor, exhibits potent antiviral activities in HCV replicon cells. Antimicrob. Agents Chemother. 50, 1813-1822 (2006).
190. Adiwijaya BS, Hare B, Caron PR et al. Rapid decrease of wild-type hepatitis C virus on telaprevir treatment. Antivir. Ther. 14, 591-595 (2009).
191. Malcolm BA, Liu R, Lahser F et al. SCH 503034, a mechanism-based inhibitor of hepatitis C virus NS3 protease, suppresses polyprotein maturation and enhances the antiviral activity of a interferon in replicon cells. Antimicrob. Agents. Chemother. 50, 1013-1020 (2006). (Pubitemid 43327807)
192. Susser S, Welsch C, Wang Y et al. Characterization of resistance to the protease inhibitor boceprevir in hepatitis C virus infected patients. Hepatology 50, 1709-1718 (2009).
193. Sarrazin C, Zeuzem S. Resistance to direct antiviral agents in patients with hepatitis C virus infection. Gastroenterology 138(2), 447-462 (2010).
194. Tong X, Chase R, Skelton A, Chen T, Wright-Minogue J, Malcom BA. Identification and analysis of fitness of resistance mutations against the HCV protease inhibitor SCH 503034 Antiviral. Res. 70, 28-38 (2006).
195. Poordad F, McCone J, Bacon BR et al. Boceprevir combined with peginterferon -2b/ribavirin for treatment-naive patients with HCV genotype 1: SPRINT 2 final results. Hepatology 52(Suppl. 1), 402A (2010) (Abstract LB-4).
196. Jacobson IM, McHutchinson JG, Dusheiko GM. Telaprevir in combination with peginterferon and ribavirin in genotype 1 HCV treatment-naive patients: final results of Phase 3 ADVANCE study. Hepatology 52(Suppl. 1), 427A (2010) (Abstract 211).
197. Sherman KE, Flamm SL, Afdhal NH et al. Telaprevir in combination with peginterferon a2a and ribavirin for 24 or 48 weeks in treatment-naive genotype 1 HCV patients who achieved an extended rapid viral response: final results of Phase 3 ILLUMINATE study. Hepatology 52(Suppl. 1), 401A (2010) (Abstract LB-2).
198. Bacon BR, Gordon SC, Lawitz E et al. HCV RESPOND 2 final results: high sustained virologic response among genotype 1 previous non-responders and relapsers to peginterferon/ribavirin when re-treated with boceprevir plus PEGINTRON (Peginterferon -2b)/ ribavirin. Hepatology 52(Suppl. 1), 430A (2010) (Abstract 216).
199. Foster GR, Zeuzem S, Andreone P et al. Telaprevir-based therapy in G1 HCV-infected patients with prior null response, partial response or relapse to peginterferon/ribavirin: REALIZE trial final results. Hepatol. Int. 5, 14 (2011) (Abstract PS02-04).
200. Reesink HW, Zeuzem S, Weegink CJ et al. Rapid decline of viral RNA in hepatitis C patients treated with VX-950: a Phase Ib, placebo-controlled, randomized study. Gastroenterology 131, 997-1002 (2006). (Pubitemid 44498690)
201. Jacobson I, Pockros P, Lalezari J et al. Antiviral activity of filibuvir in combination with pegylated interferon -2a andribavirin for 28 days in treatment-naive patients chronically infected with HCV genotype 1 J. Hepatol. 50(Suppl. 1), S382-S383 (2009).
202. Pawlotsky JM. Treatment failure and resistance with direct-αcting antiviral drugs against hepatitis C virus. Hepatology 53(5), 1742-1751 (2011).
203. Beaulieu PL. Non-nucleoside inhibitors of the HCV NS5B polymerase: progress in the discovery and development of novel agents for the treatment of HCV infections. Curr. Opin. Investig. Drugs 8, 614-634 (2007). (Pubitemid 47205246)
204. Lesburg CA, Cable MB, Ferrari E, Hong Z, Mannarino AF, Weber PC. Crystal structure of the RN-dependent RNA polymerase from hepatitis C virus reveals a fully encircled active site. Nat. Struct. Biol. 6, 937-943 (1999). (Pubitemid 29463307)
205. Chatterji U, Bobardt M, Selvarajah S et al. The isomerise active site of cyclophilin A is critical for hepatitis C virus replication. J. Biol. Chem. 284, 16998-17005 (2009).
206. Flisiak R, Horban A, Gallay P et al. The cyclophilin inhibitor Debio-025 shows potent anti-hepatitis C effect in patients coinfected with hepatitis C and human immunodeficiency virus. Hepatology 47, 817-826 (2008). (Pubitemid 351449673)
207. Flisiak R, Feinman SV, Jablkowski M et al. The cyclophilin inhibitor Debio 025 combined with PEG IFNa2a significantly reduces viral load in treatment-naive hepatitis C patients. Hepatology 49, 1460-1468 (2009).
208. Hopkins S, Heuman D, Gavis E et al. Safety, plasma pharmacokinetics, and anti-viral activity of SCY-635 in adult patients with chronic hepatitis C virus infection. J. Hepatol. 50, S36 (2009).
209. Rossignol JF, Kabil SM, El-Gohary Y, Elfert A, Keeffe EB. Clinical trial: randomized, double-blind, placebo-controlled study of nitazoxanide monotherapy for the treatment of patients with chronic hepatitis C genotype 4 Aliment. Pharmacol. Ther. 28, 574-580 (2008).
210. Korba BE, Elazar M, Lui P et al. Potential for hepatitis C virus resistance to nitazoxanide or tizoxanide. Antimicrob. Agents Chemother. 52, 4069-4071 (2008).
211. Lavillette D, Tarr AW, Voisset C et al. Characterization of host-range and cell entry properties of the major genotypes and subtypes of hepatitis C virus. Hepatology 41(2), 265-274 (2005). (Pubitemid 40173981)
212. Berg T, Hopf U, Stark K, Baumgarten R, Lobeck H, Schreier E. Distribution of hepatitis C virus genotypes in German patients with chronic hepatitis C: correlation with clinical and virological parameters. J. Hepatol. 26, 484-491 (1997). (Pubitemid 27112711)
213. Pawlotsky JM, Taskiris L, Roudot-Thoraval F et al. Relationship between hepatitis C virus genotypes and sources of infection in patients with chronic hepatitis C. J. Infect. Dis. 171, 1607-1610 (1995).
214. Watson JP, Brind AM, Chapman CE et al. Hepatitis C virus: epidemiology and genotypes in the north east of England. Gut 38, 269-276 (1996). (Pubitemid 26046825)
215. Pazienza V, Clement S, Pugnale P et al. Gene expression profile of Huh-7 cells expressing hepatitis C virus genotype1b or 3a core proteins. Liver Int. 29(5), 661-669 (2009).
216. Dou J, Liu P, Wang J, Zhang X. Preliminary analysis of gene expression profiles in HepG2 cell line induced by different genotype core proteins of HCV. Cell. Mol. Immunol. 3, 227-233 (2006).
217. Wasley A, Alter MJ. Epidemiology of hepatitis C: Aeographic differences and temporal trends. Semin. Liver Dis. 20, 1-16 (2000). (Pubitemid 30421405)
218. Gaglio PJ, Moss N, McGaw C, Reinus J. Direct-αcting antiviral therapy for hepatitis C: attitudes regarding future use. Dig. Dis. Sci. 56(5), 1509-1515 (2011).
219. Lange CM, Sarrazin C, Zeuzem S. Review article: specifically targeted anti-viral therapy for hepatitis C - a new era in therapy. Aliment. Pharmacol. Ther. 32(1), 14-28 (2010).
220. Erhardt A, Deterding K, Benhamou Y et al. Safety, pharmacokinetics and antiviral effect of BILB 1941, a novel hepatitis C virus RNA polymerase inhibitor, after 5 days oral treatment. Antivir. Ther. 14, 23-32 (2009).
221. Jiang LJ, Gai Y, Middleton T et al. Potent HCV protease inhibitors with the potential for once-daily dosing and broad genotype coverage. J. Hepatol. 50(Suppl. 1), S6 (2009).
222. Liang Y, Ishida H, Lenz O et al. Antiviral suppression vs restoration of RIG-I signaling by hepatitis C protease and polymerase inhibitors. Gastroenterology 135, 1710-1718 (2008).
223. Nettles R, Chien C, Chung E et al. BMS-790052 is a first-in-class potent hepatitis C virus (HCV) NS5A inhibitor for patients with chronic HCV infection: results from a proof-of-concept study. Hepatology 48(Suppl. 1), 1025A (2008).
224. Thompson P, Patel R, Steffy K, Appleman J. Preclinical studies of ANA598 combined with other anti-HCV agents demonstrate potential of combination treatment. J. Hepatol. 50(Suppl. 1), S37 (2009).
225. Pawlotsky JM. Therapeutic implications of hepatitis C virus resistance to antiviral drugs. Ther. Adv. Gastroenterol. 2, 205-219 (2009).
226. Kieffer TL, Sarrazin C, Miller JS et al. Telaprevir and pegylated interferon-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients. Hepatology 46, 631-639 (2007). (Pubitemid 47436107)
227. Sarrazin C, Kieffer TL, Bartels D et al. Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir. Gastroenterology 132, 1767-1777 (2007). (Pubitemid 46677938)
228. Villano S, Howe A, Raible D et al. Analysis of HCV NS5B genetic variants following monotherapy with HCV-796, a non-nucleoside polymerase inhibitor, in treatment-naive HCV-infected patients. Hepatology 44(Suppl. 1), 607-608A (2006).
229. Chevaliez S, Bouvier-αlias M, Brillet R, Pawlotsky JM. Hepatitis C virus (HCV) genotype 1 subtype identification in new HCV drug development and future clinical practice. PLoS ONE 4(12), e8209 (2009).
230. Piccoli C, Scrima R, Quarato G et al. Hepatitis C virus protein expression causes calcium-mediated mitochondrial bioenergetic dysfunction and nitro-oxidative stress. Hepatology 46(1), 58-65 (2007). (Pubitemid 47171921)
231. Lange CM, Bojunga J, Ramos-Lopez E et al. Vitamin D deficiency and a CYP27B1-1260 promoter polymorphism are associated with chronic hepatitis C and poor response to interferon-α based therapy. J. Hepatol. 54(5), 887-893 (2010).
232. Petta S, Cammà C, Scazzone C et al. Low vitamin D serum level is related to severe fibrosis and low responsiveness to interferon-based therapy in genotype 1 chronic hepatitis C. Hepatology 51(4), 1158-1167 (2007).
233. Otero RM, Marugan MT. Hepatoprotective effects of antioxidants in chronic hepatitis C. World J. Gastroenterol. 16(15), 1937-1938 (2010).
234. Peters MG, Terrault NA. Alcohol use and hepatitis C. Hepatology 36(5 Suppl. 1), S220-S225 (2002). (Pubitemid 35253484)
235. Nakamura M, Saito H, Ikeda M et al. An antioxidant resveratrol significantly enhanced replication of hepatitis C virus. World J. Gastroenterol. 16, 184-192 (2010).